Axsome Therapeutics (AXSM) Gross Profit (2022 - 2026)

Axsome Therapeutics' Gross Profit history runs 5 years deep, the most recent figure standing at $176.5 million for Q1 2026.

• In Q1 2026, Gross Profit rose 58.03% year-over-year to $176.5 million; the TTM figure through Mar 2026 stood at $655.8 million (up 136.68% YoY), while the FY2025 annual figure was $591.0 million, up 67.72% from the prior year.
• Gross Profit came in at $176.5 million for Q1 2026 at Axsome Therapeutics, down from $183.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $183.7 million in Q4 2025 to a low of -$10.0 million in Q4 2024.
• A 5-year average of $80.7 million and a median of $73.9 million in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit plunged 115.61% in 2024 and soared 1934.13% in 2025, its largest moves.
• Axsome Therapeutics' Gross Profit stood at $22.1 million in 2022, then soared by 190.54% to $64.2 million in 2023, then slumped by 115.61% to -$10.0 million in 2024, then jumped by 1934.13% to $183.7 million in 2025, then slipped by 3.92% to $176.5 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $176.5 million, $183.7 million, and $159.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison